Novogene Co

Novogene Co Working Capital Turnover

The Working Capital Turnover of Novogene Co (688315.SS) as of Oct 28, 2026 is 8.34. In the previous year, Working Capital Turnover was 1.51 — a change of 452.09% (higher).

Working Capital Turnover

8.34

YoY

452.09%

Last updated:

Working Capital Turnover of Novogene Co is 2025 8.34 . Working Capital Turnover of Novogene Co was 2024 1.51 . It decreases by 452.09% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Novogene Co Stock analysis

What does Novogene Co do? Novogene Co., Ltd. generates revenue through genomic services and solutions, primarily utilizing high-throughput sequencing and bioinformatics analysis technologies. The company offers life science basic research services, medical research and technical services, and database-building sequencing platform services, targeting both domestic and international markets. Key products include gene mutation detection kits, coronavirus disease nucleic acid test services, and DA8600 sequencers, which are sold to research institutions, medical facilities, and clinical applications. The firm's technology-driven approach enables it to provide multi-level scientific and research technical services across life science and medical fields. Novogene's revenue streams are anchored in its sequencing platforms and equipment, with the DA8600 sequencers representing a significant product line. The company develops and sells genetic testing medical equipment, leveraging its expertise in gene sequencing. Its services are tailored for life science basic research, medical and clinical applications, and database construction, serving a diverse clientele including research organizations and healthcare providers. The firm's focus on multi-omics research technology enhances its ability to deliver comprehensive solutions. The business model integrates high-throughput sequencing technology with bioinformatics analysis to create scalable services. Novogene's offerings span from basic research support to clinical diagnostic tools, with gene mutation detection kits and coronavirus disease nucleic acid test services catering to specific market needs. The company's domestic and overseas market presence ensures broad client reach, while its independent development of sequencing equipment like the DA8600 sequencers drives product-based revenue. This dual focus on services and equipment positions Novogene as a key player in genomic technology solutions. Novogene Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novogene Co stock

Working Capital Turnover of Novogene Co is 8.34 in 2025.

Working Capital Turnover of Novogene Co changed from 1.51 to 8.34, representing a 452.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Working Capital Turnover Novogene Co since 2006 – with annual values, charts, and detailed analysis.

Working capital turnover measures how efficiently a company uses its working capital to generate revenue. Higher ratios indicate more efficient short-term asset utilization.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Working Capital Turnover's Novogene Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Working Capital Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Working Capital Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Novogene Co

All Key Metrics — Novogene Co